Cytokinetics (CYTK) Tops Q4 EPS by 6c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $73.62 -0.66%
Revenue Growth %: +1,960.6%
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +1,960.6%
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($1.50), $0.06 better than the analyst estimate of ($1.56). Revenue for the quarter came in at $17.76 million versus the consensus estimate of $7.12 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Microsoft plans data center push to triple its computing power - Bloomberg
- Copart (CPRT) Misses Q4 EPS by 4c
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
